Pacer Advisors Inc. Makes New $3.81 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

Error: Response status code does not indicate success: 503 (Service Unavailable).

Pacer Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,588 shares of the biopharmaceutical company's stock, valued at approximately $3,813,000.

Other institutional investors and hedge funds have also modified their holdings of the company. First Horizon Corp grew its holdings in Alnylam Pharmaceuticals by 20.7% during the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company's stock worth $65,000 after acquiring an additional 28 shares during the period. Yousif Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company's stock valued at $666,000 after acquiring an additional 29 shares during the period. Daiwa Securities Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company's stock valued at $4,220,000 after acquiring an additional 35 shares during the period. Golden State Wealth Management LLC boosted its position in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 36 shares in the last quarter. Finally, Everpar Advisors LLC boosted its position in Alnylam Pharmaceuticals by 6.3% in the 4th quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company's stock worth $247,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $286.41 on Tuesday. The stock has a market capitalization of $38.24 billion, a P/E ratio of 78.25 and a beta of 0.29. The company's fifty day moving average price is $299.49 and its 200 day moving average price is $336.03. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals, Inc. has a 1 year low of $273.11 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm's revenue for the quarter was up 96.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.44) earnings per share. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ALNY shares. Jefferies Financial Group reaffirmed a "hold" rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Truist Financial dropped their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating on the stock in a research report on Monday, April 13th. Royal Bank Of Canada cut their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an "outperform" rating for the company in a report on Friday, May 1st. Citigroup began coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They issued a "buy" rating and a $380.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $463.13.

Insider Transactions at Alnylam Pharmaceuticals

In related news, insider Melissa Mclaughlin sold 2,286 shares of the company's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider owned 9,443 shares in the company, valued at $3,120,156.06. This represents a 19.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the firm's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,740 shares of company stock valued at $2,420,214 in the last three months. Corporate insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.